Boundless Bio, Inc. (BOLD)

Market Cap	43.71M
Revenue (ttm)	n/a
Net Income (ttm)	-61.06M
Shares Out	22.30M
EPS (ttm)	-5.21
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	329,072
Open	2.010
Previous Close	2.000
Day's Range	1.950 - 2.100
52-Week Range	1.950 - 15.240
Beta	n/a
Analysts	Buy
Price Target	22.50 (+1,047.96%)
Earnings Date	Apr 3, 2025

About BOLD

Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 28, 2024
• Employees: 72
• Stock Exchange: NASDAQ
• Ticker Symbol: BOLD
• Website: https://boundlessbio.com

Analyst Forecast

According to 3 analysts, the average rating for BOLD stock is "Buy." The 12-month stock price forecast is $22.5, which is an increase of 1,047.96% from the latest price.

Price Target

$22.5

(1,047.96% upside)

Analyst Consensus: Buy